We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.
- Authors
Simon, N; Marsot, A; Villard, E; Choquet, S; Khe, H-X; Zahr, N; Lechat, P; Leblond, V; Hulot, J-S
- Abstract
Human multidrug resistance-related protein 2 (MRP2, encoded by ABCC2) is involved in the transport of anionic drugs such as methotrexate (MTX). We prospectively investigated the influence of four common ABCC2 genetic variants (rs717620, rs2273697, rs8187694 and rs8187710) on MTX pharmacokinetics parameters. MTX concentrations were monitored in 50 patients with lymphoid malignancy (27 males; mean age: 53±17 years) receiving high-dose MTX (5.13±1.88 g m−2 in a 4-h perfusion). The population pharmacokinetics modelling showed that ABCC2 −24T allele (rs717620) had a combined influence on both MTX elimination and distribution. The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the −24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h−1, P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively. Consequently, −24T allele carriers were more prone to reach MTX nontoxic levels, 48 h after administration.
- Subjects
GENETIC polymorphisms; METHOTREXATE; DRUG dosage; PHARMACOKINETICS; LYMPHOID tissue; MULTIDRUG resistance-associated proteins; CANCER
- Publication
Pharmacogenomics Journal, 2013, Vol 13, Issue 6, p507
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/tpj.2012.37